

From: [Nicholas Mastrota](#)
To: [Joseph Okoniewski](#); smcmillin@ospr.dfg.ca.gov
Cc: [Justin Housenger](#)
Subject: Questions about screening for bromethalin
Date: 06/29/2011 05:22 PM

Joe and Stella,

We are working on an assessment of risk of rodenticides to wildlife, which includes an assessment of wildlife mortality incidents. Joe and I have already discussed that while there are few incidents attributed to bromethalin exposure, bromethalin is not often included in rodenticide screens. There is therefore a question whether the lack of incidents is due to favorable properties of the chemical, such as a short retention time in tissue, or because of lack of looking for this ingredient in the toxicity analyses, or a combination of both.

As a follow-up, I have the following questions I would like to ask both of you:

- 1) Approximately what percentage of the time do you think bromethalin is included in screenings of wildlife tissue samples for rodenticides in your state?
- 2) Do you have a procedure or process for deciding if bromethalin is included or not?
- 3) Is there any observable effects that can be seen in the necropsy exams that would suggest neurological toxicity which would cause you to check for bromethalin? Is there any biomarker for bromethalin? Or do you just consider bromethalin when there is a lack of evidence of other causes?

Thank you much for your help.

Nick Mastrota
Ecological Risk Branch 3
Environmental Fate and Effects Division
Office of Pesticide Programs